Hoth Therapeutics’ (HOTH) Buy Rating Reaffirmed at HC Wainwright

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $4.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 345.93% from the company’s current price.

Other equities analysts have also issued reports about the stock. EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a report on Friday, October 11th.

Hoth Therapeutics Stock Performance

NASDAQ HOTH opened at $0.90 on Monday. The firm’s fifty day moving average is $0.89 and its two-hundred day moving average is $0.94. Hoth Therapeutics has a one year low of $0.58 and a one year high of $1.73. The firm has a market cap of $6.19 million, a PE ratio of -0.56 and a beta of 0.84.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.15. Research analysts predict that Hoth Therapeutics will post -1.18 earnings per share for the current year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.